Tarsons Products Limited (TARSONS) — Financial Results | 1 June 2026

StockFin.ai

Try Free

Tarsons Products reported record FY'26 revenue of ₹426 crores (+7.7% YoY) and consolidated PAT of ₹112 crores (+21.5% YoY), driven by 11.7% domestic growth despite 13.4% export decline from Middle East tensions. Gross margins stood at 58.5% in Q4, pressured by raw material inflation but supported by strategic capex in bioprocessing and cell culture, with full operations expected in H1 FY'27. EBITDA reached ₹110.1 crores (28.3% margin), reflecting operational resilience amid industry-wide supply constraints and pricing pressures.

📄 View Original Announcement (PDF)

📊 Stock Analysis — TARSONS ✨ Ask AI About This

About Tarsons Products Limited (TARSONS)

Healthcare · Healthcare Equipment & Supplies · Listed on NSE

Market Cap: ₹1,101.1 Cr P/E: 36.9

View full TARSONS stock details →

📡 Get AI alerts when TARSONS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TARSONS — Free

💡 Ask AI about this filing

"How does this financial results affect Tarsons Products Limited's outlook?" "What did Tarsons Products Limited announce on 1 June 2026?" "Is this positive or negative for TARSONS?"

Ask AI Free →

📊 More TARSONS filings

See all TARSONS filings →

🔥 Also filed on 1 June 2026

RAINBOW Rainbow Childrens Medicare Limited Financial Results RBLBANK RBL Bank Limited Announcement PRUDMOULI Prudential Sugar Corporation Limited Financial Results PUNJLLOYD Punj Lloyd Limited Financial Results RADIANTCMS Radiant Cash Management Services Limited Financial Results RBLBANK RBL Bank Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when TARSONS files new disclosures

Track TARSONS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TARSONS — Free

Free account · 2 AI queries/day